Regulation

AFC Gamma, Inc. Announces Financial Results for First Quarter 2022

Retrieved on: 
Tuesday, May 10, 2022
Board, Trust, U.S. Securities and Exchange Commission, PIK, Investment, CECL, Regulation Fair Disclosure, GAAP, Quarter, FDIC, NASDAQ, Cannabis, GLOBE, Regulation, Disclosure, Security (finance), Depreciation, AFC, Investor relations, Total, PALM, Income, REIT, Conference, SEC, Management, Solution, Growth, Eastern Time Zone, Investor, Mobile phone, Cryptocurrency, Online gambling, Bank, Renewable energy, Video game, Lithium, Real estate, Dividend distribution tax

WEST PALM BEACH, Fla., May 10, 2022 (GLOBE NEWSWIRE) -- AFC Gamma, Inc. (NASDAQ:AFCG) (AFCG or AFC Gamma) today announced its results for the first quarter of 2022.

Key Points: 
  • WEST PALM BEACH, Fla., May 10, 2022 (GLOBE NEWSWIRE) -- AFC Gamma, Inc. (NASDAQ:AFCG) (AFCG or AFC Gamma) today announced its results for the first quarter of 2022.
  • AFCG issued a presentation of its first quarter 2022 results, titled First Quarter 2022 Earnings Presentation, which can be viewed at www.afcgamma.com under the Investor Resources section.
  • AFCG also filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, with the Securities and Exchange Commission on May 10, 2022.
  • AFC Gamma, Inc. will host a conference call at 10:00 am (Eastern Time) on Tuesday, May 10, 2022, to discuss its quarterly financial results.

EzFill Celebrates Educators on Teachers Appreciation Day with The Gift of Fuel

Retrieved on: 
Tuesday, May 10, 2022
Workplace, Forward-looking statement, Student, Gift, NASDAQ, GLOBE, Â, Company, Safety, Shell, Mitsubishi, Industry, Exxon, Consumer, GM, CEO, Regulation, Tutoring, Online shopping

MIAMI, FL, May 10, 2022 (GLOBE NEWSWIRE) -- EzFill Holdings, Inc. (“EzFill” or the “Company”) (NASDAQ: EZFL), a pioneer and emerging leader in the on-demand mobile fuel industry, celebrated educators on Teachers Appreciation Day at Mizrahi Torah Academy in Plantation, Florida last week with free gas fill-ups for every teacher.

Key Points: 
  • The school, which educates boys and girls in kindergarten through elementary and middle school, surprised its staff on Teachers Appreciation Day with the EzFill Gift of Fuel.
  • With fuel costs near an all-time high, the Gift of Fuel is an especially helpful and timely way for the Mizrahi Torah Academy to say thank you to its educators on Teachers Appreciation Day, said Mike McConnell, CEO of EzFill.
  • The EzFill App allows consumers to fill up their vehicles without leaving the comfort and safety of their home or workplace.
  • EzFill is a leader in the fast-growing mobile fuel industry, with the largest market share in its home state of Florida.

Cellectar Reports Financial Results for First Quarter 2022 and Provides a Corporate Update

Retrieved on: 
Tuesday, May 10, 2022
COVID-19, U.S. Securities and Exchange Commission, Drug discovery, Mission statement, DMC, Multiple myeloma, Twitter, Christian democracy, NASDAQ, GLOBE, PDC, Lymphoma, Development, Travel, Safety, Research, Neuroblastoma, State Administrative Expenses, Patient, Hand, Security (finance), Review, FDA, Cancer, Sarcoma, Exchange, Marketing, LinkedIn, Cash, CEO, News, G&A, Regulation, Brain, Risk, Pharmaceutical industry, WM, Facebook

FLORHAM PARK, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc.(NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced financial results for the first quarter ended March 31, 2022 and provided a corporate update.

Key Points: 
  • FLORHAM PARK, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc.(NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced financial results for the first quarter ended March 31, 2022 and provided a corporate update.
  • Net cash used in operating activities during the three months ended March 31, 2022 was approximately $5.0 million.
  • The company believes its cash on hand is adequate to fund basic budgeted operations for at least 12 months from the filing of the first quarter 2022 financial statements.
  • These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.

CoCo Farms Parent Kolaboration Ventures Launches Reg A+ Equity Financing

Retrieved on: 
Tuesday, May 10, 2022
Farm, Offering, CPG, US, LLC, KVC, Cannabis, GLOBE, Company, Regulation, Common stock, RIO, Offering circular, 2021–22 NCAA football bowl games, Sale, Super Bowl, Biomass, Regulation A, Life, CEO, Share (finance), State, Growth, Drug

RIO VISTA, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Kolaboration Ventures Corporation ("KVC" or the "Company"), a leading vertically integratedcannabis brand and operator in California, has launched a Regulation A, equity financing (the "Offering") (see Kolaboration VenturesOffering Circular ).

Key Points: 
  • RIO VISTA, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Kolaboration Ventures Corporation ("KVC" or the "Company"), a leading vertically integratedcannabis brand and operator in California, has launched a Regulation A, equity financing (the "Offering") (see Kolaboration VenturesOffering Circular ).
  • Kolaboration Ventures is strategically positioned to become the consumer and retailer product of choice among adult-use and medical cannabis consumers.
  • "We want to provide our customers and supporters with the opportunity to invest in a growing and vertically integrated cannabis operation," said Martin Wesley, CEO of Kolaboration Ventures Corporation.
  • Kolaboration Ventures Corporation (KVC) is one of the largest vertically-integrated cannabis operators in the largest cannabis market in the country, California.

Inhibikase Therapeutics to Participate at the H.C. Wainwright Global Investment Conference

Retrieved on: 
Tuesday, May 10, 2022
Neurodegeneration, YouTube, Brain, Regulation Fair Disclosure, Imatinib, Twitter, Nasdaq, Multiple system atrophy, Company, Regulation, Therapy, Disclosure, Parkinson's disease, RAMP, LinkedIn, GI, Conference, SEC, Pharmaceutical industry, Facebook

BOSTON and ATLANTA, May 10, 2022 /PRNewswire/ --Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced that Dr. Milton Werner, Ph.D., the Company's President & Chief Executive Officer will present at the upcoming H.C. Wainwright Global Investment Conference being held in Miami Beach, FL on May 25, 2022 at 2:30 pm ET.

Key Points: 
  • BOSTON and ATLANTA, May 10, 2022 /PRNewswire/ --Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced that Dr. Milton Werner, Ph.D., the Company's President & Chief Executive Officer will present at the upcoming H.C. Wainwright Global Investment Conference being held in Miami Beach, FL on May 25, 2022 at 2:30 pm ET.
  • Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders.
  • Inhibikase's multi-therapeutic pipeline focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain.
  • Inhibikase is headquartered in Atlanta, Georgia with offices in Boston, Massachusetts.

GCM Grosvenor Reports First Quarter 2022 with 10% Growth in Assets Under Management, 86% Growth in GAAP Net Income and 26% Growth in Adjusted Net Income

Retrieved on: 
Tuesday, May 10, 2022
Board, GCMG, COVID-19, Board of directors, Forward-looking statement, Investment, Private Securities Litigation Reform Act, GAAP, LLLP, Adjustment, GCM, U.S. Securities and Exchange Commission, GCM Grosvenor, EBITDA, GLOBE, TRA, Depreciation, Partnership, Webcast, FRE, Annual report, QTD, FRR, Income, Solution, AUM, Regulation, Assets under management, Security (finance), Financial adviser, Bank, Online gambling, Financial services, Mosaic

The first quarter of 2022 was a good one for GCM Grosvenor with regard to fundraising, revenue growth, and profitability, said Michael Sacks, Chairman and Chief Executive Officer of GCM Grosvenor.

Key Points: 
  • The first quarter of 2022 was a good one for GCM Grosvenor with regard to fundraising, revenue growth, and profitability, said Michael Sacks, Chairman and Chief Executive Officer of GCM Grosvenor.
  • GCM Grosvenors experienced team of approximately 520 professionals serves a global client base of institutional and high net worth investors.
  • This press release includes certain non-GAAP financial measures, including fee-related revenue, fee-related earnings, adjusted pre-tax income, adjusted net income, adjusted EBITDA and net incentive fees attributable to GCM Grosvenor.
  • GCM Grosvenor believes that these non-GAAP measures of financial results provide useful supplemental information to investors about GCM Grosvenor.

VYNE Hosting Key Opinion Leader Event on Novel InhiBET™ BET Inhibitor Platform

Retrieved on: 
Tuesday, May 10, 2022
Melasma, Innovation, Department, University, KOL, Regulation Fair Disclosure, Laboratory, U.S. Securities and Exchange Commission, Nasdaq, GLOBE, Teaching hospital, Chromatin, Alopecia areata, Journal, Laser, Regulation, Disclosure, BRD4, Metabolism, Patient, Hidradenitis suppurativa, Doctor of Philosophy, Mixed-phenotype acute leukemia, Boston University School of Medicine, Review, Breast, Association, BET, Inflammation, BRD3, Cancer, Family, Pigment, Therapy, American Association, MD, Publication, Limited, BRD2, Electric Bond and Share Company v. Securities and Exchange Commission, Prostate Cancer Foundation, Protein, Research, X-linked reticulate pigmentary disorder, Vitiligo, Melanoma, Pharmaceutical industry, Dermatology

BRIDGEWATER, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (VYNE or the Company), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that it will hold a virtual Key Opinion Leader (KOL) event on VYNEs InhiBET BET Inhibitor Platform on Tuesday, May 17, 2022 at 10:00 a.m.

Key Points: 
  • BRIDGEWATER, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (VYNE or the Company), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that it will hold a virtual Key Opinion Leader (KOL) event on VYNEs InhiBET BET Inhibitor Platform on Tuesday, May 17, 2022 at 10:00 a.m.
  • An archived version of the event will be available in the Investors & Media, Events and Presentations section of the VYNE website for 90 days.
  • The BET protein field has grown from sixteen papers, when he first published his work, to over 1,600 to date.
  • The BET inhibitor platform includes lead programs VYN201 (pan-BETi) and VYN202 (selective-BETi) and access to a library of (BET) domain inhibitors for the potential treatment of immuno-inflammatory conditions.

OptimizeRx to Participate in Upcoming May Conferences

Retrieved on: 
Tuesday, May 10, 2022
Forward-looking statement, Private Securities Litigation Reform Act, GLOBE, Company, Patient, Organization, Intention, Conference, U.S. Securities and Exchange Commission, Technology, Regulation, Pharmaceutical industry, Real estate, Health insurance

Details for the RBC Healthcare Conference fireside chat are as follows:

Key Points: 
  • Details for the RBC Healthcare Conference fireside chat are as follows:
    Management will also be available for in-person one-on-one meetings.
  • Details for the B. Riley Annual Institutional Conference presentation can be found below:
    Management will also be available for in-person one-on-one meetings.
  • OptimizeRx is the best-in-class health technology company enabling care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey.
  • Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.

Frontier Prices $1.2 Billion of First Lien Secured Notes and Increases Revolving Credit Facility

Retrieved on: 
Tuesday, May 10, 2022
Technology, Networks, Internet, Telecommunications, OTT, COVID-19, Forward-looking statement, Information technology, Chapter 11, Title 11, United States Code, Infection, CAF, U.S. Securities and Exchange Commission, NASDAQ, LLC, Digital divide, Tax, Company, Regulation, Public expenditure, Securities Act of 1933, Form, Safety, SEC Rule 144A, Legislation, Program, Risk, Person, Environment, Industry, Compliance, Epidemic, Form 10-K, History, Note, Lists of disasters, Health, Income, Pandemic, Sale, SEC, SOFR, Frontier, Acquisition, Security (finance), Bank

Frontier Communications Holdings, LLC (the Issuer), a consolidated subsidiary of Frontier Communications Parent, Inc. (NASDAQ: FYBR) (Frontier) today announced the pricing of its previously announced private offering of $1.2 billion aggregate principal amount of first lien secured notes due 2030 (the Notes).

Key Points: 
  • Frontier Communications Holdings, LLC (the Issuer), a consolidated subsidiary of Frontier Communications Parent, Inc. (NASDAQ: FYBR) (Frontier) today announced the pricing of its previously announced private offering of $1.2 billion aggregate principal amount of first lien secured notes due 2030 (the Notes).
  • The Notes will bear interest at 8.750% per year and will be sold at a price equal to 100% of the aggregate principal amount.
  • Frontier also announced an increase to its senior secured first lien revolving credit facility (the Revolving Facility) by an additional $275 million, to a total of $900 million in aggregate principal amount of revolving credit commitments.
  • The Revolving Facility was also amended to reflect SOFR based interest rates (including a customary credit spread adjustment).

Khiron achieves United Kingdom Cannabis Sales Volume Growth of 240% in Q1 2022

Retrieved on: 
Tuesday, May 10, 2022
Comment, Board of directors, Population, Nature, Company, Legislation, Patient, Risk, Acquisition, Prescription, CAD, Multimedia, SEDAR, Intention, Regulation, Growth, Drug, Fine chemical, Khiron Oonchaiyaphum

This growth is generated by Khiron's end-to-end solution of government regulation, supply chain, distribution, and clinics prescribing Khiron's medical cannabis products.

Key Points: 
  • This growth is generated by Khiron's end-to-end solution of government regulation, supply chain, distribution, and clinics prescribing Khiron's medical cannabis products.
  • With a population of almost 67 million, the UK has a potential of at least 1.5% medical cannabis patients1.
  • Khiron addresses the great potential in the UK with its medical cannabis products and clinical services, which are increasingly used by patients and medical practitioners.
  • In Q1 2022 and beyond, Europe will represent over 50% of Khiron's cannabis revenues, strengthening Khiron's position as a leader in the global medical cannabis market."